Advanced search
Publication Cover
OncoImmunology Volume 3, 2014 - Issue 6
Submit an article Journal homepage
794
Views
15
CrossRef citations to date
0
Altmetric
Author's View

Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis

<span lang="EN-US">Glycans make the difference</span>

Diego O Croci Laboratorio de Inmunopatología; Instituto de Biología y Medicina Experimental (IBYME); Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Buenos Aires, Argentina
&
Gabriel A Rabinovich Laboratorio de Inmunopatología; Instituto de Biología y Medicina Experimental (IBYME); Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Buenos Aires, Argentina; Laboratorio de Glicómica; Departamento de Química Biológica,; Facultad de Ciencias Exactas y Naturales; Universidad de Buenos Aires; Buenos Aires, ArgentinaCorrespondence[email protected]
Article: e29380 | Received 24 May 2014, Accepted 27 May 2014, Published online: 25 Jun 2014

References

  • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182 - 6; http://dx.doi.org/10.1056/NEJM197111182852108; PMID: 4938153
  • Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12:5018 - 22; http://dx.doi.org/10.1158/1078-0432.CCR-06-1520; PMID: 16951216
  • Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298 - 307; http://dx.doi.org/10.1038/nature10144; PMID: 21593862
  • Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592 - 603; http://dx.doi.org/10.1038/nrc2442; PMID: 18650835
  • Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013; 19:1114 - 23; http://dx.doi.org/10.1038/nm.3291; PMID: 23913124
  • Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36:322 - 35; http://dx.doi.org/10.1016/j.immuni.2012.03.004; PMID: 22444630
  • Dennis JW, Nabi IR, Demetriou M. Metabolism, cell surface organization, and disease. Cell 2009; 139:1229 - 41; http://dx.doi.org/10.1016/j.cell.2009.12.008; PMID: 20064370
  • Thijssen VL, Rabinovich GA, Griffioen AW. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev 2013; 24:547 - 58; http://dx.doi.org/10.1016/j.cytogfr.2013.07.003; PMID: 23942184
  • Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma. J Exp Med 2012; 209:1985 - 2000; http://dx.doi.org/10.1084/jem.20111665; PMID: 23027923
  • Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014; 156:744 - 58; http://dx.doi.org/10.1016/j.cell.2014.01.043; PMID: 24529377

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.